age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults.

In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States. In Japan it is approved for bipolar depression and schizophrenia. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia.

Few available atypical antipsychotics are known

1.Previous
3.Next